Day: March 26, 2024

TORONTO, March 26, 2024 (GLOBE NEWSWIRE) — PROBE GOLD INC. (TSX-V: PRB) (OTCQB: PROBF) (“Probe” or the “Company”) is pleased to announce the filing of the independent Preliminary Economic Assessment (“PEA”) technical report  which has been prepared in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects, on its 100% owned Novador Project, located in Val-d’Or, Québec. The Novador PEA supports a robust mining plan that averages over 255,000 ounces per year of gold production, with over 281,000 ounces per year in the first five years of the 12.6-year mine life and boasts an impressive after-tax NPV of $910 million using a base-case gold price of US$1,750/oz. The technical report, entitled “Novador Project, NI 43-101 Technical Report & Preliminary Economic Assessment” (the “Novador...

For a limited time, get a Galaxy S23 with Galaxy AI on us with a new line on Verizon myPlan¹ NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) — Verizon customers will soon be able to experience Samsung One UI 6.1 with Galaxy AI2 on additional Samsung smartphones beyond the Galaxy S24 series. This expansion includes popular models, such as the Galaxy S23 series, Galaxy S23 FE, Galaxy Z Fold5 and Galaxy Z Flip5. With this update, you can unlock a host of innovative features to enhance your life, work and mobile experience. Verizon Galaxy S23 Offer: Check everything Galaxy AI has to offer with this amazing deal. For a limited time, get a new Galaxy S23 on us when you purchase your new phone with a new line on myPlan – no trade-in required1. Whether you’re upgrading to the Galaxy S23 series, Galaxy S23 FE, Galaxy Z Fold5 and Galaxy Z Flip5,...

LA JOLLA, Calif., March 26, 2024 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of macular injury associated with progressive multiple sclerosis. Once issued, this patent is expected to expire no earlier than October 2039.  The allowed claims cover the use of MN-166 (ibudilast) for treating macular injury associated with progressive multiple sclerosis and for decreasing macular volume loss associated with progressive multiple sclerosis. The allowed claims specifically cover both primary progressive multiple sclerosis and secondary...

2023 Sustainability ReportAttachmentRS2023_EN_v.25032024

HENDERSON, Nev., March 26, 2024 (GLOBE NEWSWIRE) — Movella Holdings Inc. (NASDAQ: MVLA) (“Movella” or the “Company”), a leading full-stack provider of sensors, software, and analytics that enable the digitization of movement, announced today that it was notified by the Nasdaq Stock Market LLC (“Nasdaq”) of the timing of Nasdaq’s planned suspension of trading of the Company’s securities. As previously disclosed in its Current Report filed on Form 8-K with the Securities and Exchange Commission (the “SEC”) on March 20, 2024 (the “8-K”), the Company notified Nasdaq of the Company’s decision to voluntarily delist its shares of common stock, par value $0.00001 per share (the “Common Stock”) and its warrants exercisable for one share of Common Stock at an exercise price of $11.50 (the “Warrants” and together with the Common Stock, the...

EDMONTON, Alberta, March 26, 2024 (GLOBE NEWSWIRE) — Regenx Tech Corp., (the “Corporation” or “Regenx“) (CSE: RGX) (OTCQB: RGXT) (FSE: YRS WKN: A2DSW3) announced that it will be offering rights (the “Rights Offering“) to holders of its common shares (“Common Shares“) of record at the close of business on April 2, 2024 (the “Record Date”). Pursuant to the Rights Offering, each holder of Common Shares (a “Shareholder”) will receive one (1) transferable right (each, a “Right”) for each Common Share held as of the Record Date. One (1) Right will entitle the holder thereof to subscribe for one Common Share upon payment of the subscription price of $0.0075 (3/4 of a cent) per Common Share until 5:00 p.m. (Toronto time) (the “Expiry Time”) on May 21, 2024. Assuming the exercise of all Rights,...

NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) — AMC Networks Inc. (“AMC Networks” or the “Company”) (Nasdaq: AMCX) today announced that it has priced an offering of $875 million aggregate principal amount of 10.25% senior secured notes due 2029 (the “Notes”) in a private offering, which represents an increase of $175 million in aggregate principal amount of the Notes from the amount announced at the launch of the offering. The Notes will be unconditionally guaranteed, on a joint and several basis, by each of AMC Networks’ existing and future domestic subsidiaries, subject to certain exceptions, on a senior secured basis. AMC Networks expects to use the net proceeds from the offering of the Notes to fund its tender offer (the “Tender Offer”) to purchase for cash any and all of its outstanding approximately $775 million of 4.75% Senior...

LONDON, March 27, 2024 (GLOBE NEWSWIRE) — Lightpoint Surgical Limited (Lightpoint), an affiliate of Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a world-first bladder cancer sentinel lymph node (SLN) procedure with SENSEI®, Telix’s miniature robotic-assisted gamma probe used to detect radiation in patients and guide surgery. The patient was operated on at Hospital del Mar in Barcelona, Spain. SENSEI® is smaller than an AA battery and designed specifically for robotic-assisted and minimally invasive surgery. The miniature size and proprietary features make the technology ideal for tight surgical spaces such as around the bladder. With broad application in radio-guided surgery across multiple procedures and major cancer types, SENSEI® is currently indicated for use during SLN biopsy in prostate,...